Letter: immunotherapy for IBD patients in a SARS-CoV-2 endemic area-authors' reply

Carlos Taxonera; Iñigo Sagastagoitia; Cristina Alba

doi:10.1111/apt.15955

Letter: immunotherapy for IBD patients in a SARS-CoV-2 endemic area-authors' reply

Aliment Pharmacol Ther. 2020 Sep;52(5):900-901. doi: 10.1111/apt.15955.

Authors

Carlos Taxonera¹, Iñigo Sagastagoitia², Cristina Alba¹

Affiliations

¹ Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos (IdISSCJY V), Madrid, Spain.
² Department of Internal Medicine, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Abstract

LINKED CONTENT

This article is linked to Taxonera et al and Szokodi papers. To view these articles, visit https://doi.org/10.1111/apt.15804 and https://doi.org/10.1111/apt.15897

Publication types

Letter
Comment